| SEC Form 4 |  |
|------------|--|
|------------|--|

П

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
|  |
| Section 16. Form 4 or Form 5           |
| obligations may continue. See          |
| Instruction 1(b).                      |

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

## OMB APPROVAL OMB Number: 3235-0287

| hours per response:      |  | 0.5 |  |
|--------------------------|--|-----|--|
| Estimated average burden |  |     |  |
|                          |  |     |  |

| 1. Name and Addre            | ss of Reporting Person<br>NTHONY C | n*         | 2. Issuer Name and Ticker or Trading Symbol <u>AMGEN INC</u> [ AMGN ] | (Check                 | tionship of Reporting Persc<br>all applicable)<br>Director<br>Officer (give title | on(s) to Issuer<br>10% Owner<br>Other (specify |  |
|------------------------------|------------------------------------|------------|---|------------------------|---|--|--|
| (Last)<br>ONE AMGEN (        | (First)<br>CENTER DRIVE            | (Middle)   | 3. Date of Earliest Transaction (Month/Day/Year)<br>04/27/2014        | X                      | below)<br>EVP, Global Comme   | below)   |  |
| (Street)<br>THOUSAND<br>OAKS | CA                                 | 91320-1799 | 4. If Amendment, Date of Original Filed (Month/Day/Year)              | 6. Indiv<br>Line)<br>X | ,   |  |  |
| (City)                       | (State)                            | (Zip)      |   |                        | reisun  |  |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |      | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5)<br>e (Instr. |        | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |          |  |
|---------------------------------|--|---|------|---|--------|---|---|---|---|----------|--|
|                                 |  |   | Code | v   | Amount | (A) or<br>(D)   | Price   | Transaction(s)<br>(Instr. 3 and 4)                                |   | (1150.4) |  |
| Common Stock                    | 04/27/2014                                 |   | F    |   | 1,490  | D   | \$111.41  | 114,720   | D |          |  |
| Common Stock                    | 04/27/2014                                 |   | F    |   | 56     | D   | \$111.41  | 114,664 <sup>(1)(2)</sup>   | D |          |  |

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of |  | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr. 3<br>and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | Ownership<br>Form:<br>Direct (D) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|----|--|--|--------------------|---|--|---|--|----------------------------------|--|
|   |   |  |   | Code                         | v |    |  | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |                                  |  |

#### Explanation of Responses:

1. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 7,239 RSUs which vest in one installment on 3/2/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively: 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2016 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis

2. These shares include 417 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

### <u>/s/ Anthony C. Hooper</u>

\*\* Signature of Reporting Person

04/2<u>9/2014</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.